Umoja Biopharma
Likely to Engage tag.Highly Engaged Employees

Business Services · Washington, United States · 51-200 Employees

View Company Info for Free

Overview

Headquarters

1150 Eastlake Ave E Ste 400, Seattle, Wa...

Revenue

$40.2 Million

Industry

Business Services Research & Development

About Umoja Biopharma

Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja's novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.Explore more
Umoja Biopharma's Social MediaSIC Code 87,873NAICS Code 54,541Show more

Umoja Biopharma Org Chart

PhoneEmail
Ryan Crisman, Co-Founder & Chief Technology Officer at Umoja Biopharma
United States flag for contact location.

Co-Founder & Chief Technology Officer

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
TK
United States flag for contact location.

Vice President, Analytical Development

Flame icon indicating likelihood to engage via phone.PhoneFlame icon indicating likelihood to engage via email.Email

PhoneEmail
Get the full picture
Sign in to uncover key details.

Compare Similar Companies to Umoja Biopharma

Compare insights from companies similar to Umoja Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Umoja Biopharma

$40.2M
51-200
Private
$363M
2019
Ryan Crisman, Co-Founder & Chief Technology Officer at Umoja Biopharma
Ryan CrismanCo-Founder & Chief Technology Officer
$18.8M
51-200
Private
$243.5M
2015
$14.9M
51-200
Private
-
1996
JC
Jeremy CromerManager, Regulatory Affairs
$11.9M
51-200
Private
-
2014
N/A
$9.1M
51-200
Private
-
2009
CA
Carol AoSales Department
$8.4M
51-200
Private
-
2015
JU
Jeffrey UcranChief Operating Officer
$5.4M
51-200
Private
-
2008
RF
Rémi FromentinPostdoctoral Researcher
Illustration of an envelope

Umoja Biopharma Tech Stack

A closer look at the technologies used by Umoja Biopharma

Top Business Services Companies

Frequently Asked Questions Regarding Umoja Biopharma

What is Umoja Biopharma's official website?
Umoja Biopharma's official website is www.umoja-biopharma.com
What is Umoja Biopharma's Revenue?
Umoja Biopharma's revenue is $40.2 Million
What is Umoja Biopharma's SIC code?
Umoja Biopharma's SIC: 87,873
What is Umoja Biopharma's NAICS code?
Umoja Biopharma's NAICS: 54,541
How many employees does Umoja Biopharma have?
Umoja Biopharma has 51-200 employees
What industry does Umoja Biopharma belong to?
Umoja Biopharma is in the industry of: Business Services, Research & Development
What is Umoja Biopharma competition?
Umoja Biopharma top competitors include: Dragonfly Therapeutics, Vaccine & Gene Therapy Institute of Florida, Genitope, StemImmune
What technology does Umoja Biopharma use?
Some of the popular technologies that Umoja Biopharma uses are: DocuSign, WooCommerce, WordPress.org, PHP
Who is the CTO of Umoja Biopharma?
Umoja Biopharma's CTO is Ryan Crisman
What does Umoja Biopharma do?

Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja's novel approach is powered by integrated cellular immunotherapy technologies... including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.Read More

What are Umoja Biopharma social media links?
Umoja Biopharma Linkedin page Umoja Biopharma Twitter page
Who invested in Umoja Biopharma?
Umoja Biopharma has 27 investors including DCVC Management, SoftBank Group Corp, MPM Capital and Qiming Venture Partners USA.
Is Umoja Biopharma a public company?
Umoja Biopharma is private company therefore does not currently have an official ticker symbol
See more information about Umoja Biopharma

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.